Brought to you by 
Celyad nets $93.1mm in global offering on NASDAQ
22 Jun 2015
Executive Summary
Cell therapy company Celyad SA netted $93.1mm in its US initial public offering of 1.5mm American Depository Shares (ADS) at $68.57 (€60.25) on NASDAQ. The company sold 1.2mm ordinary shares in the form of ADSs in the US and Canada and 300k ordinary shares in Europe and outside the US and Canada through a concurrent PIPE.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celyad nets $93.1mm in global offering on NASDAQ
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice